Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: A phase iv, open-label, prospective, randomized study

Acta Haematologica

Volumn 121, Issue 1, 2009, Pages 37-41

  Kim, Yun Hwan ^a   Chung, Hyun Hoon ^a   Kang, Soon Beom ^a,d   Kim, Seung Cheol ^b   Kim, Young Tae ^c  

^a Seoul National University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

Intravenous iron therapy; Iron deficiency anemia; Menorrhagia; Oral iron

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMO Q SOLN; HEMOGLOBIN; IRON PROTEIN SUCCINYLATE; UNCLASSIFIED DRUG; VENOFERRUM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION PAIN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MENORRHAGIA; MULTICENTER STUDY; MYALGIA; NAUSEA; PERIOPERATIVE PERIOD; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANEMIA; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; MENORRHAGIA; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES;

EID: 63049092549     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210062     Document Type: Article

References (23)

1. Cole SK, Billewicz WZ, Thomson AM: Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commonw 1971; 78: 933-939.
2. Hallberg L, Hogdahl AM, Nilsson L, Rybo G: Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45: 320-351.
3. Oehler MK, Rees MC: Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82: 405-422.
4. Coulter A, Peto V, Jenkinson C: Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994; 11: 394-401.
5. Shaw RW, Brickley MR, Evans L, Edwards MJ: Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. Br J Obstet Gynaecol 1998; 105: 1155-1159.
6. Kuriyan M, Carson JL: Anemia and clinical outcomes. Anesthesiol Clin North Am 2005; 23: 315-325, vii.
7. Carson JL, Terrin ML, Jay M: Anemia and postoperative rehabilitation. Can J Anaesth 2003; 50:S60-S64.
8. Liguori L: Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1,000 patients. Int J Clin Pharmacol Ther Toxicol 1993; 31: 103-123.
9. Coplin M, Schuette S, Leichtmann G, Lashner B: Tolerability of iron: a comparison of bis-glycino iron II and ferrous sulfate. Clin Ther 1991; 13: 606-612.
10. Farley PC, Foland J: Iron deficiency anemia. How to diagnose and correct. Postgrad Med 1990; 87: 89-93, 96, 101.
11. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A: Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106: 1335-1340.
12. Bhandal N, Russell R: Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006; 113: 1248-1252.
13. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J: Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503-2509.
14. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapyrelated anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
15. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37: 300-307.
16. Perewusnyk G, Huch R, Huch A, Breymann C: Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex. Br J Nutr 2002; 88: 3-10.
17. Sifakis S, Angelakis E, Papadopoulou E, Stratoudakis G, Fragouli Y, Koumantakis E: The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. Clin Exp Obstet Gynecol 2005; 32: 117-122.
18. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Langstrom B, Danielson BG: Pharmacokinetics and red cell utilization of iron(III) hydroxide- sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 1999; 104: 296-302.
19. Bastani B, Rahman S, Gellens M: Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran. ASAIO J 2002; 48: 404-406.
20. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33: 464-470.
21. Macdougall I, Bailie G, Richardson D, Tanner J, Gagnon SP: Worldwide safety profile of iron sucrose injection (Venofer): analysis of 1,044,477 patients from 1992 to 2001. J Am Soc Nephrol 2001; 2001: 333A.
22. Alexander DA, Naji AA, Pinion SB, Mollison J, Kitchener HC, Parkin DE, Abramovich DR, Russell IT: Randomised trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: psychiatric and psychosocial aspects. BMJ 1996; 312: 280-284.
23. Thornton EW, McQueen C, Rosser R, Kneale T, Dixon K: A prospective study of changes in negative mood states of women undergoing surgical hysterectomy: the relationship to cognitive predisposition and familial support. J Psychosom Obstet Gynaecol 1997; 18: 22-30.